Nap B.V. Forgrowth Sells 166,011 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Stock Down 2.7 %

Shares of NASDAQ NAMS opened at $25.89 on Thursday. The business’s fifty day moving average price is $21.01 and its 200-day moving average price is $18.86. NewAmsterdam Pharma has a one year low of $10.29 and a one year high of $27.29.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. raised its position in shares of NewAmsterdam Pharma by 5.1% in the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after purchasing an additional 628,251 shares during the period. Janus Henderson Group PLC lifted its position in shares of NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after acquiring an additional 520,772 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after acquiring an additional 217,902 shares during the period. Jennison Associates LLC boosted its holdings in shares of NewAmsterdam Pharma by 8.9% in the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock worth $16,937,000 after acquiring an additional 83,115 shares during the period. Finally, Deerfield Management Company L.P. Series C grew its position in shares of NewAmsterdam Pharma by 30.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after purchasing an additional 202,250 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NAMS shares. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Scotiabank raised their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $36.20.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.